Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jeffrey Kramer

Internal Medicine Walterboro, SC Medical Doctor

NPI 1588618169 CMS profile 162703

873 Robertson Blvd, Walterboro, SC 29488

Open in the dashboard

General payments

$5,768

292 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jeffrey Kramer of Walterboro, SC is reported in the CMS Open Payments database as having received $5,768 across 292 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 90th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $964 38
2024 General $601 21
2023 General $586 25
2022 General $969 49
2021 General $1,040 61
2020 General $759 44
2019 General $848 54

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jeffrey Kramer
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Jeffrey Kramer were reported at $964. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Jeffrey Kramer Internal Medicine median Middle half National median
2019 $848 $159 $48–$570 $163
2020 $759 $119 $33–$402 $114
2021 $1,040 $135 $37–$521 $132
2022 $969 $141 $42–$496 $149
2023 $586 $149 $45–$519 $160
2024 $601 $154 $47–$537 $164
2025 $964 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $1,091 51 payments
  2. Lilly USA, LLC $854 41 payments
  3. Novo Nordisk Inc $593 36 payments
  4. GlaxoSmithKline, LLC. $452 31 payments
  5. Exact Sciences Corporation $292 7 payments
  6. Janssen Pharmaceuticals, Inc $262 16 payments
  7. AbbVie, Inc. $233 14 payments
  8. Boehringer Ingelheim Pharmaceuticals, Inc. $216 10 payments
  9. Bayer HealthCare Pharmaceuticals Inc. $205 7 payments
  10. Pfizer Inc. $181 11 payments
  11. Other $1,390 68 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,723 291 payments
  2. Education $45 1 payment
Products named General payments · program years 2019–2025
  1. FARXIGA $594 30 payments
  2. Ozempic $473 27 payments
  3. TRULICITY $370 25 payments
  4. BREZTRI $353 14 payments
  5. RYBELSUS $285 17 payments
  6. XARELTO $262 16 payments
  7. TRELEGY ELLIPTA $254 15 payments
  8. MOUNJARO $250 8 payments
  9. JARDIANCE $247 16 payments
  10. Kerendia $205 7 payments
  11. Other $3,776 203 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 157 drugs

Part D claims

9,208

Median for Internal Medicine: 777

Drug cost

$994,636

Median for Internal Medicine: $73,373

Branded share of claims

24.7%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Mounjaro Tirzepatide Brand 92 $141,020
Eliquis Apixaban Brand 126 $117,319
Jardiance Empagliflozin Brand 87 $86,799
Farxiga Dapagliflozin Propanediol Brand 84 $71,283
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 61 $70,363
Ozempic Semaglutide Brand 48 $55,955
Trulicity Dulaglutide Brand 33 $41,252
Creon Lipase/Protease/Amylase Brand 11 $39,021
Myrbetriq Mirabegron Brand 56 $38,576
Januvia Sitagliptin Phosphate Brand 30 $36,483

The 10 drugs with the highest cost, of 157 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 47 billing codes

Paid by Medicare

$280,499

Of which drugs: $4,708

Medicare patients

599

Average age 75

Services billed

5,221

332 women, 267 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 48%
Diabetes 35%
Chronic kidney disease 26%
Ischemic heart disease 22%
Depression 22%
COPD 20%
Heart failure 16%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Influenza vaccine, trivalent derived from cell cultures 90661 Office 128 128 $4,550
Injection, ketorolac tromethamine, per 15 mg J1885 Office 34 176 $89
Injection, methylprednisolone sodium succinate, 5 mg J2919 Office 11 300 $60

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 15 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $124
$124 — —
MOUNJARO
  • Lilly USA, LLC $78
$78 92 —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $62
$62 84 —
TRELEGY ELLIPTA
  • GlaxoSmithKline, LLC. $26
$26 61 —
LEQVIO
  • Novartis Pharmaceuticals Corporation $17
$17 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 15 in the dashboard with a free account

Records

292 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in South Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record